|
1
|
Cardoso F, Harbeck N, Barrios CH, Bergh J,
Cortés J, El Saghir N, Francis PA, Hudis CA, Ohno S, Partridge AH,
et al: Research needs in breast cancer. Ann Oncol. 28:208–217.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhai Q, Li H, Sun L, Yuan Y and Wang X:
Identification of differentially expressed genes between triple and
non-triple-negative breast cancer using bioinformatics analysis.
Breast Cancer. 26:784–791. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mouh FZ, Mzibri ME, Slaoui M and Amrani M:
Recent progress in triple negative breast cancer research. Asian
Pac J Cancer Prev. 17:1595–1608. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yuan Q, Zheng L, Liao Y and Wu G:
Overexpression of CCNE1 confers a poorer prognosis in
triple-negative breast cancer identified by bioinformatic analysis.
World J Surg Oncol. 19:862021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pratama MY, Pascut D, Massi MN and
Tiribelli C: The role of microRNA in the resistance to treatment of
hepatocellular carcinoma. Ann Transl Med. 7:5772019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ding L, Gu H, Xiong X, Ao H, Cao J, Lin W,
Yu M, Lin J and Cui Q: MicroRNAs involved in carcinogenesis,
prognosis, therapeutic resistance and applications in human
triple-negative breast cancer. Cells. 8:14922019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cheng H, Dong H, Feng J, Tian H, Zhang H
and Xu L: miR-497 inhibited proliferation, migration and invasion
of thyroid papillary carcinoma cells by negatively regulating YAP1
expression. Onco Targets Ther. 11:4711–4721. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Huang Q, Li H, Dai X, Zhao D, Guan B and
Xia W: miR-497 inhibits the proliferation and migration of A549
non-small-cell lung cancer cells by targeting FGFR1. Mol Med Rep.
20:3959–3967. 2019.PubMed/NCBI
|
|
9
|
Xu GS, Li ZW, Huang ZP, Brunicardi FC, Jia
F, Song C, Zou HJ and Sun RF: MiR-497-5p inhibits cell
proliferation and metastasis in hepatocellular carcinoma by
targeting insulin-like growth factor 1. Mol Genet Genomic Med.
7:e008602019. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wei C, Luo Q, Sun X, Li D, Song H, Li X,
Song J, Hua K and Fang L: MicroRNA-497 induces cell apoptosis by
negatively regulating Bcl-2 protein expression at the
posttranscriptional level in human breast cancer. Int J Clin Exp
Pathol. 8:7729–7739. 2015.PubMed/NCBI
|
|
11
|
Li G, Wang K, Wang J, Qin S, Sun X and Ren
H: miR-497-5p inhibits tumor cell growth and invasion by targeting
SOX5 in non-small-cell lung cancer. J Cell Biochem.
120:10587–10595. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang L, Li K, Lin X, Yao Z, Wang S, Xiong
X, Ning Z, Wang J, Xu X, Jiang Y, et al: Metformin induces human
esophageal carcinoma cell pyroptosis by targeting the miR-497/PELP1
axis. Cancer Lett. 450:22–31. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ma W, Feng W, Tan J, Xu A, Hu Y, Ning L,
Kang Y, Wang L and Zhao Z: miR-497 may enhance the sensitivity of
non-small cell lung cancer cells to gefitinib through targeting the
insulin-like growth factor-1 receptor. J Thorac Dis. 10:5889–5897.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Overholtzer M, Zhang J, Smolen GA, Muir B,
Li W, Sgroi DC, Deng CX, Brugge JS and Haber DA: Transforming
properties of YAP, a candidate oncogene on the chromosome 11q22
amplicon. Proc Natl Acad Sci U S A. 103:12405–12410. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pan D: The hippo signaling pathway in
development and cancer. Dev Cell. 19:491–505. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Johnson R and Halder G: The two faces of
hippo: Targeting the hippo pathway for regenerative medicine and
cancer treatment. Nat Rev Drug Discov. 13:63–79. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zheng Y and Pan D: The hippo signaling
pathway in development and disease. Dev Cell. 50:264–282. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Deng X and Fang L: VGLL4 is a
transcriptional cofactor acting as a novel tumor suppressor via
interacting with TEADs. Am J Cancer Res. 8:932–943. 2018.PubMed/NCBI
|
|
19
|
Hua K, Yang W, Song H, Song J, Wei C, Li D
and Fang L: Up-regulation of miR-506 inhibits cell growth and
disrupt the cell cycle by targeting YAP in breast cancer cells. Int
J Clin Exp Med. 8:12018–12027. 2015.PubMed/NCBI
|
|
20
|
Cao L, Sun PL, Yao M, Jia M and Gao H:
Expression of YES-associated protein (YAP) and its clinical
significance in breast cancer tissues. Hum Pathol. 68:166–174.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhu C, Li L, Zhang Z, Bi M, Wang H, Su W,
Hernandez K, Liu P, Chen J, Chen M, et al: A non-canonical Role of
YAP/TEAD is required for activation of estrogen-regulated enhancers
in breast cancer. Mol Cell. 75:791–806.e8. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu X, Zhou Y, Ning YE, Gu H, Tong Y and
Wang N: MiR-195-5p inhibits malignant progression of cervical
cancer by targeting YAP1. Onco Targets Ther. 13:931–944. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang Q, Ding J, Nan G, Lyu Y and Ni G:
LncRNA NOC2L-4.1 functions as a tumor oncogene in cervical cancer
progression by regulating the miR-630/YAP1 pathway. J Cell Biochem.
120:16913–16920. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hu XH, Dai J, Shang HL, Zhao ZX and Hao
YD: miR-1285-3p is a potential prognostic marker in human
osteosarcoma and functions as a tumor suppressor by targeting YAP1.
Cancer Biomark. 25:1–10. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Thakur V and Kutty RV: Recent advances in
nanotheranostics for triple negative breast cancer treatment. J Exp
Clin Cancer Res. 38:4302019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Piasecka D, Braun M, Kordek R, Sadej R and
Romanska H: MicroRNAs in regulation of triple-negative breast
cancer progression. J Cancer Res Clin Oncol. 144:1401–1411. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sánchez-González I, Bobien A, Molnar C,
Schmid S, Strotbek M, Boerries M, Busch H and Olayioye MA: miR-149
suppresses breast cancer metastasis by blocking paracrine
interactions with macrophages. Cancer Res. 80:1330–1341. 2020.
View Article : Google Scholar
|
|
29
|
Lee SJ, Jeong JH, Kang SH, Kang J, Kim EA,
Lee J, Jung JH, Park HY and Chae YS: MicroRNA-137 inhibits cancer
progression by targeting Del-1 in triple-negative breast cancer
cells. Int J Mol Sci. 20:61622019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shen L, Li J, Xu L, Ma J, Li H, Xiao X,
Zhao J and Fang L: miR-497 induces apoptosis of breast cancer cells
by targeting Bcl-w. Exp Ther Med. 3:475–480. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Luo QF, Li XY, Gao Y, Long Y, Chen L,
Huang YX and Fang L: MiRNA-497 regulates cell growth and invasion
by targeting cyclin E1 in breast cancer. Cancer Cell Int.
13:952013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tu Y, Liu L, Zhao D, Liu Y, Ma X, Fan Y,
Wan L, Huang T, Cheng Z and Shen B: Overexpression of miRNA-497
inhibits tumor angiogenesis by targeting VEGFR2. Sci Rep.
5:138272015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Guo ST, Jiang CC, Wang GP, Li YP, Wang CY,
Guo XY, Yang RH, Feng Y, Wang FH, Tseng HY, et al: MicroRNA-497
targets insulin-like growth factor 1 receptor and has a tumour
suppressive role in human colorectal cancer. Oncogene.
32:1910–1920. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Li C, Wang S and Yang C: Long non-coding
RNA DLX6-AS1 regulates neuroblastoma progression by targeting YAP1
via miR-497-5p. Life Sci. 11:1176572020. View Article : Google Scholar
|
|
35
|
Duan Y, Zhao M, Jiang M, Li Z and Ni C:
LINC02476 promotes the malignant phenotype of hepatocellular
carcinoma by sponging miR-497 and increasing HMGA2 expression. Onco
Targets Ther. 13:2701–2710. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Andrade D, Mehta M, Griffith J,
Panneerselvam J, Srivastava A, Kim TD, Janknecht R, Herman T,
Ramesh R and Munshi A: YAP1 inhibition radiosensitizes triple
negative breast cancer cells by targeting the DNA damage response
and cell survival pathways. Oncotarget. 8:98495–98508. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Cheng H, Zhang Z, Rodriguez-Barrueco R,
Borczuk A, Liu H, Yu J, Silva JM, Cheng SK, Perez-Soler R and
Halmos B: Functional genomics screen identifies YAP1 as a key
determinant to enhance treatment sensitivity in lung cancer cells.
Oncotarget. 7:28976–28988. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Guo L, Chen Y, Luo J, Zheng J and Shao G:
YAP1 overexpression is associated with poor prognosis of breast
cancer patients and induces breast cancer cell growth by inhibiting
PTEN. FEBS Open Bio. 9:437–445. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lee JY, Chang JK, Dominguez AA, Lee HP,
Nam S, Chang J, Varma S, Qi LS, West RB and Chaudhuri O:
YAP-independent mechanotransduction drives breast cancer
progression. Nat Commun. 10:18482019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Li Z, Ge X, Lu J, Bian M, Li N, Wu X, Li
Y, Yan M and Yu J: MiR-141-3p regulates proliferation and
senescence of stem cells from apical papilla by targeting YAP. Exp
Cell Res. 383:1115622019. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chen M, Wu L, Tu J, Zhao Z, Fan X, Mao J,
Weng Q, Wu X, Huang L, Xu M and Ji J: miR-590-5p suppresses
hepatocellular carcinoma chemoresistance by targeting YAP1
expression. EBioMedicine. 35:142–154. 2018. View Article : Google Scholar : PubMed/NCBI
|
